SA PRO
Free Account
EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 88% recommend buying.

Consensus Rating
Buy
17 analysts·Moderate coverage
88%
Rating Distribution
Strong Buy
00%
Buy
1588%
Hold
212%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Oct 29, 2025Mizuho Securities
EyePoint price target raised to $33 from $28 at Mizuho
Target:$33.00
+169.4%from $12.25
Oct 20, 2025Mizuho Securities
Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
Target:$28.00
+140.8%from $11.63
Nov 11, 2024H.C. Wainwright
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright
Target:$22.00
+89.9%from $11.59
May 13, 2024H.C. Wainwright
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at H.C. Wainwright
Target:$30.00
+146.5%from $12.17
May 7, 2024Mizuho Securities
EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at Mizuho
Target:$30.00
+167.9%from $11.20
Aug 4, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $25
Target:$25.00
+144.6%from $10.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance